We captured adult individuals of Panamanian rocket frog (Colostethus panamansis) using clean, inverted plastic freezer bags. For each frog, we measured mass to the nearest 0.01 g, and snout-vent length (SVL) to the nearest 0.1 mm using calipers and Pesola scales. We also collected skin swab samples to test for Bd presence and infection intensity using standardized swabbing techniques. To collect frog skin secretions, we induced each frog to secrete its store of secretions from cutaneous granular glands by administering a stimulatory injection of norepinephrine (NE) below the skin surface (Rollins-Smith et al. 2005, Woodhams et al. 2006). We randomly assigned frogs to one of three NE treatment groups: a high-dose treatment, hereafter referred to as the "Reduced" group, a low-dose treatment, hereafter referred to as the "Partially Reduced" group, and a "Control" group that received an injection of sterile saline solution. Following reduction of skin secretions, we used capture-mark-recapture (CMR) to identify frogs and collect additional diagnostic samples to test for Bd infection. This approach allowed us to track infection status over time. We used a quantitative polymerase chain reaction (qPCR) assay to assess prevalence and intensity of Bd infection in our diagnostic samples that were collected over the course of the field experiment. We also collected skin secretions samples from common rocket frogs (Colostethus panamansis) at two sites (OTNP1, OTNP2), across seasons (wet, dry). To collect frog skin secretions, we used the same method described above. In total 50 samples were analyzed using MALDI-TOF (Biosystems Voyager Elite mass spectrometer (Applied Biosystems, Foster City, California, USA) operated in reflector, delayed extraction, and positive ion mode. We prepared peptide samples by spotting peptides onto a MALDI plate in a 1:1 ratio with matrix [10 mg/ml α-cyano-4-hydroxycinnamic acid (Fluka, Sigma, St. Louis, MO), 60% acetonitrile, 39.6% HPLC-grade water, and 0.4% trifluoroacetic acid (v/v/v)]. Each sample was analyzed by averaging signals from 256 consecutive laser shots. The MS data was acquired in the m/z range 500 to 7,000, truncated at m/z 4,500 and baseline-corrected with Data Explorer v4.4 (Applied Biosystems). Data are in .csv file with sheets: 1. Peptide recovery 2. CMR Infection data 3. Seasonal Infection data 4. Peptide effectiveness data 1. Peptide recovery ID: individual frog identification Treatment: treatment group Mass: mass (g) Peptide recovered (mg/g body weight) 2. CMR Infection data ID: individual frog identification Numerical date: day of sample collection Pre_Post: prior to or after experimental treatments Treatment: treatment group Infected: Bd positive or negative Log PCR: log transformed genomic equivalents of Bd 3. Seasonal Infection data ID: individual frog identification Season: WET or DRY Season_2: numerical season of sample collection Site: site of sample collection Infected: Bd positive or negative Log PCR: log transformed genomic equivalents of Bd 4. Peptide effectiveness data ID: individual frog identification Season: WET or DRY Season_2: numerical season of sample collection Site: site of sample collection PE: peptide effectiveness Infected: Bd positive or negative M1438-m2970: presence or absence of peptide